<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03352947</url>
  </required_header>
  <id_info>
    <org_study_id>INTERIM</org_study_id>
    <secondary_id>2016-005228-27</secondary_id>
    <secondary_id>PB-PG-0815-20048</secondary_id>
    <nct_id>NCT03352947</nct_id>
  </id_info>
  <brief_title>Continuous vs Intermittent Dabrafenib Plus Trametinib in BRAFV600 Mutant Stage 3 Unresectable or Metastatic Melanoma</brief_title>
  <acronym>INTERIM</acronym>
  <official_title>INTERIM: a Randomised Phase II Feasibility Study of INTERmittent Versus Continuous Dosing or Oral Targeted Combination Therapy in Patients With BRAFV600 Mutant Stage 3 Unresectable or Metastatic Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cambridge University Hospitals NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute for Health Research, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oxford University Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cambridge University Hospitals NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This feasibility study aims to determine if intermittent dosing is deliverable, based on&#xD;
      patient and professional willingness to take part in a randomised trial evaluating less&#xD;
      rather than the standard durations of treatment. The trial will evaluate treatment&#xD;
      compliance, Progression Free Survival and Quality of Life, to inform whether a subsequent&#xD;
      definitive trial is justified and how it should be designed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Metastatic melanoma has a very poor prognosis: median overall survival is 8 months untreated&#xD;
      and around 2 years even with optimal systemic therapies. A gene called BRAF is abnormal in&#xD;
      about half of melanomas and biological agents targeting the BRAF pathway have been shown to&#xD;
      extend life. They are now routinely available in NHS clinical practice.&#xD;
&#xD;
      Giving BRAF and MEK inhibitor drugs together offers the best anti-cancer treatment for these&#xD;
      patients. However, treatment is limited by side-effects (often affecting the skin) and&#xD;
      secondary resistance (which means the cancer regrows usually after about a year).&#xD;
&#xD;
      Laboratory experiments and case reports suggest intermittent dosing of these chronic orally&#xD;
      administered drugs makes BRAF pathway inhibitors work for longer, extending life and reducing&#xD;
      side effects. The INTERIM trial aims to test whether less treatment than usual is acceptable&#xD;
      to patients and doctors and, potentially, more beneficial. The INTERIM trial also aims to&#xD;
      develop better tools to monitor skin side-effects.&#xD;
&#xD;
      The target population will be male and female participants aged 18 and over with BRAFV600&#xD;
      mutant stage 3 unresectable or metastatic melanoma.Patients will be provided with information&#xD;
      regarding the trial both through conversation with investigators and research nurses and in&#xD;
      writing via a patient information sheet. Patients will be given time to ask questions and&#xD;
      discuss with family/support structures before deciding to participate. If the patient agrees&#xD;
      to take part, they will be asked to provide written consent.&#xD;
&#xD;
      Visit schedule for consenting patients:&#xD;
&#xD;
      Screening:&#xD;
&#xD;
      Consenting patients will enter the screening/baseline phase, which will be completed within&#xD;
      28 days prior to randomisation. This will include assessing the patient against inclusion &amp;&#xD;
      exclusion criteria.&#xD;
&#xD;
      Randomisation:&#xD;
&#xD;
      If eligible, patients will be randomly assigned to either treatment arms using a web-based&#xD;
      central randomisation system. Patients will be randomised on a 1:1 basis to one of 2 arms:&#xD;
&#xD;
      Control arm: dabrafenib 150mg twice daily and trametinib 2mg once daily, taken by mouth&#xD;
      continuously on a 4 week cycle Experimental arm: dabrafenib 150mg twice daily x 3 weeks and&#xD;
      trametinib 2mg once daily x 2 weeks, on a 4 week cycle&#xD;
&#xD;
      On treatment:&#xD;
&#xD;
      During the first two cycles of treatment patients will attend the hospital every two weeks&#xD;
      (on days 1 and 15 of the cycle) where they will have a clinical review.&#xD;
&#xD;
      From cycle 3 onwards patients will attend the hospital only on day 1 of the cycle.&#xD;
&#xD;
      If patients are on treatment for more than 52 weeks, clinic visits can be every other cycle&#xD;
      with telephone follow-up between to ensure patient review is at least every 4 weeks until&#xD;
      progression.&#xD;
&#xD;
      End of Treatment:&#xD;
&#xD;
      At the end of treatment an additional clinical visit will be performed to review the patient.&#xD;
      If at the time of treatment cessation patients have not met the criteria for disease&#xD;
      progression they will be followed up every 4 weeks. After 52 weeks since randomisation there&#xD;
      will be the option of clinic visits every 8 weeks with telephone follow-up in between.&#xD;
&#xD;
      Disease progression:&#xD;
&#xD;
      Patients will have a clinical visit at the time of protocol-defined disease progression.&#xD;
&#xD;
      Follow-up after disease progression:&#xD;
&#xD;
      Patients will attend hospital every three months after disease progression for a minimum of 9&#xD;
      months from randomisation.&#xD;
&#xD;
      Trial procedures:&#xD;
&#xD;
      Clinical review &amp; physical examinations:&#xD;
&#xD;
      Patients will be reviewed by the trial team during the screening period, at every treatment&#xD;
      and follow-up visit. This will involve recording any medications they may be taking, and any&#xD;
      symptoms and/or side-effects they may have. Patients will also have a physical examination,&#xD;
      and assessment of blood pressure as part of this review, and the clinical team will assess&#xD;
      the patient's clinical status using ECOG and Karnofsky performance status scales.&#xD;
&#xD;
      Baseline skin assessment &amp; skin toxicity questionnaires:&#xD;
&#xD;
      At screening the patient and clinician will be asked to complete a questionnaire about the&#xD;
      baseline condition of the patient's skin. If during treatment there are any skin-related&#xD;
      adverse events both the patient and clinician will be asked to complete a skin toxicity&#xD;
      questionnaire.&#xD;
&#xD;
      Compliance assessment:&#xD;
&#xD;
      During treatment at each clinical visit the patient will be asked to bring their medication&#xD;
      along with their diary card.The clinical team will record how many tablets remain and how&#xD;
      many tablets have been taken. The patient will be asked to record in the diary card the date&#xD;
      and time when they take their medication. Both of these activities will be used to assess the&#xD;
      patient's compliance to the treatment regimen.&#xD;
&#xD;
      Pregnancy test:&#xD;
&#xD;
      Women of child bearing potential will have a pregnancy test at screening to ensure they are&#xD;
      not pregnant and are therefore able to receive the trial drugs.&#xD;
&#xD;
      Electrocardiogram (ECG):&#xD;
&#xD;
      An ECG test is required before starting the trial.&#xD;
&#xD;
      Echocardiogram (ECHO):&#xD;
&#xD;
      An ECHO is required prior to starting the trial in patients with a history of cardiac&#xD;
      problems, in patients with no cardiac history and a normal ECG it must be performed within&#xD;
      two weeks of starting trial drug. ECHOs will subsequently be performed as standard of care,&#xD;
      the recommended frequency is during cycle 4 and every 12 weeks thereafter to ensure that&#xD;
      patients are tolerating the trial drugs well.&#xD;
&#xD;
      Blood samples (routine and research):&#xD;
&#xD;
      Patients will be asked to have routine blood tests (FBC, renal, liver, bone profiles, LDH) to&#xD;
      ensure that they are fit enough for the trial, and that they are tolerating the drug well.&#xD;
      These blood samples will be taken at every clinical visit during treatment and at disease&#xD;
      progression.&#xD;
&#xD;
      Patients will also be asked to give extra blood for research related to this trial. The&#xD;
      samples will be used to measure circulating tumour DNA (ctDNA). An extra blood sample will be&#xD;
      taken every 2 weeks for the first two cycles of treatment, every 4 weeks for the next two&#xD;
      cycles, then every 8 weeks, and at disease progression.&#xD;
&#xD;
      Patients will be asked if they wish to participate in optional pharmacokinetic sampling. This&#xD;
      will involve collection of 9 blood samples on both cycle 1 day 1, and cycle 2 day 15 at&#xD;
      timepoints after they have taken their tablets. Additionally, 3 blood samples would be taken&#xD;
      if their disease progresses.&#xD;
&#xD;
      Tumour assessments:&#xD;
&#xD;
      Patients will have an initial CT scan of body and head during the screening period. Scans&#xD;
      will be repeated between days 8-15 of cycle 2 and then every 8 weeks until the end of&#xD;
      treatment. If treatment continues beyond 52 weeks imaging can be reduced to every 12 weeks.&#xD;
      If the initial screening head scan is clear, the head scan only requires repeating at every&#xD;
      other assessment.&#xD;
&#xD;
      Quality of Life questionnaires:&#xD;
&#xD;
      Patients will be asked to fill in questionnaires about their quality of life at screening on&#xD;
      day 1 of cycle 2, and then every12 weeks until the end of participation in the trial.&#xD;
&#xD;
      Tumour Tissue collection:&#xD;
&#xD;
      Upon starting treatment patients will be asked to donate previously archived tissue collected&#xD;
      for research purposes. If patients undergo surgical resection or biopsy during the course of&#xD;
      the trial for progressive disease, a tumour sample will be requested for this research.&#xD;
&#xD;
      Patient Experience survey:&#xD;
&#xD;
      Patient who do not consent to participate in the trial will be asked to complete a&#xD;
      questionnaire to explore their reasons for declining. Additionally, patients who do&#xD;
      participate in the trial will be asked to complete patient experience questionnaires after&#xD;
      consent and after 9 months participation in the trial. These questionnaires will ask the&#xD;
      patients about their experience of participating in the trial and any toxicity they&#xD;
      experienced.&#xD;
&#xD;
      Patients may continue on allocated treatment as long as they benefit from the treatment and&#xD;
      it is tolerable. Patients will be followed for a minimum of 9 months from randomisation to a&#xD;
      maximum of 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 3, 2017</start_date>
  <completion_date type="Actual">November 27, 2020</completion_date>
  <primary_completion_date type="Actual">March 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>INTERIM is a multi-centre, open label, two arm, randomised phase II feasibility trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recruitment Rate</measure>
    <time_frame>To be assessed once the trial has been recruiting for 15 months, or when 15 sites have been open for 6 months whichever is sooner</time_frame>
    <description>Average number of patients recruited per site per two months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment compliance</measure>
    <time_frame>6 months from randomisation</time_frame>
    <description>percentage of patients completing the allocated treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Quality of Life</measure>
    <time_frame>6 months from randomisation</time_frame>
    <description>global health status score derived from (EORTC) QLQ-C30 questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression Free survival</measure>
    <time_frame>calculated as the duration from the date of randomisation to the date of first progression or death from any cause, whichever occurs first, assessed up to 5 years</time_frame>
    <description>Assessed according to standard Response Criteria in Solid Tumours (RECIST v1.1)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment emergent adverse events (safety and tolerability)</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Assess using standard cancer National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) V4.03)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>assessed according to RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Time from starting drug treatment (day 1, cycle 1) until day 1 of last cycle + 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Assessed up to 5 years</time_frame>
    <description>calculated as duration from date of randomisation to the date of death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Outcomes focusing on skin toxicity evaluation</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>assessed using skin-specific patient reported outcome measures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Experience</measure>
    <time_frame>Surveys at screening and after 9 months. Interviews by invitation at a later date</time_frame>
    <description>Surveys of patients in both arms of the trial. Semi-structured interview in a subset of patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact on Quality of Life</measure>
    <time_frame>At 6 months from baseline</time_frame>
    <description>Using EORTC QLQ-C30 questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Economic Evaluation</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Using EQ-5D 5L questionnaire</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Kinetics of BRAF mutation load in each arm of the trial</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>using blood and tumour tissue taken from recruited patients</description>
  </other_outcome>
  <other_outcome>
    <measure>Emerging genetic changes associated with acquired resistance</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>using blood and tumour tissue taken from recruited patients</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">79</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>Continuous (Standard)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dabrafenib 150mg twice daily 12 hours apart, on days 1-28 of a 28 day cycle plus Trametinib 2mg once daily, on days 1-28 of a 28 day cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intermittent (experimental)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dabrafenib 150mg twice daily 12 hours apart, on days 1-21 of a 28 day cycle plus Trametinib 2mg once daily, on days 1-14 of a 28 day cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabrafenib</intervention_name>
    <description>150mg Dabrafenib twice daily day 1-21 of 28 day cycle in intermittent arm Day 1-28 of 28 day cycle in continuous arm</description>
    <arm_group_label>Continuous (Standard)</arm_group_label>
    <arm_group_label>Intermittent (experimental)</arm_group_label>
    <other_name>Tafinlar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trametinib</intervention_name>
    <description>Trametinib 2mg once daily Day 1-14 of a 28 day cycle in intermittent arm Day 1-28 of a 28 day cycle in the continuous arm</description>
    <arm_group_label>Continuous (Standard)</arm_group_label>
    <arm_group_label>Intermittent (experimental)</arm_group_label>
    <other_name>Mekinist</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Age â‰¥18 years old&#xD;
&#xD;
          -  Histologically or cytologically confirmed BRAFV600 mutant stage 3 unresectable or&#xD;
             metastatic melanoma&#xD;
&#xD;
          -  Measurable disease by RECIST&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Minimum life expectancy 12 weeks&#xD;
&#xD;
          -  Adequate bone marrow, renal and liver function&#xD;
&#xD;
          -  Received no prior BRAF or MEK inhibitor therapy for metastatic disease&#xD;
&#xD;
          -  Willing and able to comply with the scheduled visits, treatment plans, laboratory&#xD;
             tests, completion of QoL questionnaires and other study procedures&#xD;
&#xD;
          -  Archival tumour tissue sample available&#xD;
&#xD;
          -  Women of child-bearing potential and all sexually active male patients must agree to&#xD;
             use effective contraception methods throughout treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Concomitant immunotherapy being administered to treat advanced melanoma&#xD;
&#xD;
          -  Other invasive malignancies diagnosed within the last year which are not in complete&#xD;
             remission, or for which additional therapy is required&#xD;
&#xD;
          -  Significant acute or chronic medical or psychiatric condition, disease or laboratory&#xD;
             abnormality which in the judgment of the investigator would place the patient at undue&#xD;
             risk or interfere with the trial&#xD;
&#xD;
          -  Women who are pregnant, plan to become pregnant or are lactating during the trial&#xD;
             period&#xD;
&#xD;
          -  Other investigational anti-cancer drugs&#xD;
&#xD;
          -  Use of strong inducers and inhibitors of CYP3A or CYP2C8&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pippa Corrie, FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Addenbrookes</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <state>England</state>
        <zip>CB2 2QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>November 9, 2017</study_first_submitted>
  <study_first_submitted_qc>November 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 24, 2017</study_first_posted>
  <last_update_submitted>December 4, 2020</last_update_submitted>
  <last_update_submitted_qc>December 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cambridge University Hospitals NHS Foundation Trust</investigator_affiliation>
    <investigator_full_name>CCTU- Cancer Theme</investigator_full_name>
    <investigator_title>Consultant and Associate Lecturer in Medical Oncology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trametinib</mesh_term>
    <mesh_term>Dabrafenib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>PID will not be shared with other researchers. PID will not be moved from participating sties. Patient will be identified by their initials, date of birth and trial number.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 21, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/47/NCT03352947/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

